IP Library › Patent Application 13873833
Patent Application
App. No. 13/873,833

CIS-2-METHYLSPIRO 1, 3-OXATHIOLANE 5-3 QUINUCLIDINE

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/873,833
Abstract

Pharmaceutical-grade compounds containing cis-2-methylspiro(1,3-oxathiolane-5,3′)quinuclidine having a purity >99.0% by HPLC with less than 0.5% of trans-2-methylspiro(1,3-oxathiolane-5,3′)quinuclidine are provided.

Claims (3)

1 . A compound containing cis-2-methylspiro(1,3-oxathiolane-5,3′)quinuclidine having a purity >99.0% by HPLC with less than 0.5% of trans-2-methylspiro(1,3-oxathiolane-5,3′)quinuclidine.

2 . The compound according to claim 1 wherein the cis-2-methylspiro(1,3-oxathiolane-5,3′)quinuclidine is a hydrochloride or hydrate form thereof.

3 . The compound according to claim 1 wherein the cis-2-methylspiro(1,3-oxathiolane-5,3′)quinuclidine is in the form of a pharmaceutically acceptable salt or organic or inorganic acid addition salt thereof.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 4, 2021
From: MYLAN API US LLC
To: MYLAN LABORATORIES LIMITED
Reel/Frame 057685/0916 →
CHANGE OF NAME Recorded Oct 4, 2021
From: APICORE US LLC
To: MYLAN API US LLC
Reel/Frame 057697/0758 →
RELEASE OF SECURITY INTEREST Recorded Jan 9, 2017
From: KNIGHT THERAPEUTICS INC.
To: APICORE LLC
Reel/Frame 040904/0362 →
RELEASE OF SECURITY INTEREST Recorded Jan 9, 2017
From: KNIGHT THERAPEUTICS INC.
To: APICORE US LLC
Reel/Frame 040904/0390 →
SECURITY INTEREST Recorded Jul 8, 2014
From: APICORE US LLC
To: KNIGHT THERAPEUTICS INC., AS AGENT
Reel/Frame 033281/0920 →
SECURITY INTEREST Recorded Jul 3, 2014
From: APICORE LLC
To: KNIGHT THERAPEUTICS INC., AS AGENT
Reel/Frame 033277/0320 →